文献速递心律失常冠心病

房颤合并冠心病患者口服抗凝药联合抗血小板治疗的比较

Combining Oral Anticoagulants With Platelet Inhibitors in Patients With Atrial Fibrillation and Coronary Disease.
PubMed 文献 · J Am Coll Cardiol · 2018-01-01

该研究基于丹麦全国登记数据,纳入2011年8月至2017年6月因心肌梗死和/或接受PCI的房颤患者3222例,比较DOAC与VKA联合抗血小板治疗的12个月结局。结果显示DOAC+DAPT较VKA+DAPT显著降低出血风险,而DOAC+SAPT较VKA+SAPT显著降低心肌梗死风险,血栓栓塞保护相似。

要点

  • 房颤合并心梗/PCI患者中,DOAC+DAPT较VKA+DAPT出血风险更低。
  • DOAC+SAPT较VKA+SAPT心肌梗死风险更低,出血与卒中无显著差异。
  • DOAC联合抗血小板治疗血栓栓塞保护与VKA相当。

核心结论

  • 在房颤合并心梗和/或PCI的真实世界人群中,DOAC+DAPT较VKA+DAPT显著降低出血风险且血栓栓塞保护相似。

研究设计与样本

  • 基于丹麦全国登记的前瞻性队列研究,纳入2011年8月至2017年6月因心梗和/或接受PCI的房颤患者3222例,随访12个月。

主要发现

  • DOAC+SAPT较VKA+SAPT的3个月心肌梗死绝对风险差为-1.53%(95%CI -3.08%至-0.11%),出血、缺血性卒中及全因死亡无显著差异。
  • DOAC+DAPT较VKA+DAPT的3个月出血绝对风险差为-1.96%(95%CI -3.46%至-0.88%),全因死亡、卒中及心肌梗死绝对风险无显著差异。

临床怎么用

  • 对于房颤合并心梗和/或PCI需联合抗血小板治疗的患者,可优先考虑DOAC而非VKA以降低出血风险。

局限性

  • 观察性登记研究可能存在未测量混杂,结果需随机对照试验验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The optimal treatment strategy when combining antiplatelets with oral anticoagulants in patients with atrial fibrillation (AF) and myocardial infarction (MI) or undergoing percutaneous coronary intervention (PCI) is unknown. OBJECTIVES: The authors investigated the risk of bleeding, ischemic stroke, MI, and all-cause mortality associated with direct oral anticoagulants (DOACs) compared with vitamin K antagonists (VKAs) in combination with aspirin, clopidogrel, or both in patients with AF following MI and/or PCI. METHODS: Danish nationwide registries were used to identify patients with AF who were admitted with a MI and/or underwent PCI, between August 2011 and June 2017, treated with OAC in combination with antiplatelet(s). Patients were followed for 12 months or until an outcome, study end, or death. Standardized absolute risks were estimated on the basis of outcome-specific Cox regression models adjusted for potential confounders. Average treatment effects were obtained as standardized absolute risk differences (ARD) in risks at 3 and 12 months using the g-formula. RESULTS: Overall, 3,222 patients were included in the study population, of which 875 (27%) were treated with VKA+single antiplatelet therapy (SAPT), 595 (18%) were treated with DOAC+SAPT, 1,074 (33%) were treated with VKA+dual antiplatelet therapy (DAPT), and 678 (22%) were treated with DOAC+DAPT. At 3 months, there was a significant difference in the absolute risk of MI associated with DOAC+SAPT compared with VKA+SAPT (3-month ARD -1.53% (95% confidence interval: -3.08% to -0.11%), with no significant differences found regarding bleeding, ischemic stroke, and all-cause mortality. Compared with VKA+DAPT, DOAC+DAPT was associated with a significantly reduced risk of bleeding (3-month ARD -1.96%, 95% confidence interval: -3.46% to -0.88%), with no significant difference in the absolute risk of all-cause mortality, stroke, or MI. CONCLUSIONS: In a real-world population of AF patients with MI and/or after PCI, the authors found that DOAC in combination with DAPT was associated with a significantly decreased risk of bleeding and similar thromboembolic protection compared with VKA in combination with DAPT.

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Sindet-Pedersen C, Lamberts M, Staerk L, et al. Combining Oral Anticoagulants With Platelet Inhibitors in Patients With Atrial Fibrillation and Coronary Disease. J Am Coll Cardiol. 2018. PMID: 30286922. doi:10.1016/j.jacc.2018.07.054

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。